Quote | Dermata Therapeutics Inc. Warrant (NASDAQ:DRMAW)
Last: | $0.0147 |
---|---|
Change Percent: | 100.0% |
Open: | $0 |
Close: | $0.0147 |
High: | $0 |
Low: | $0 |
Volume: | 15 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
News | Dermata Therapeutics Inc. Warrant (NASDAQ:DRMAW)
- STAR-1 topline results expected in first quarter of 2025 - - About 30 million acne patients seek treatment in the U.S. each year - - DMT310, if approved, could be the first once-weekly topical product for the treatment of acne - SAN DIEGO, CA / ACCESSWIRE / July 17, 2024 / Derm...
SAN DIEGO, CA / ACCESSWIRE / May 17, 2024 / Dermata Therapeutics, Inc. (Nasdaq:DRMA)(Nasdaq:DRMAW) ("Dermata," or the "Company"), a late-stage biotechnology company focused on the treatment of medical and aesthetic skin diseases and conditions, today announced the entry into definitive agreement...
Message Board Posts | Dermata Therapeutics Inc. Warrant (NASDAQ:DRMAW)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
Dermata Therapeutics Inc. Warrant Company Name:
DRMAW Stock Symbol:
NASDAQ Market:
Dermata Therapeutics Inc. Warrant Website:
- STAR-1 topline results expected in first quarter of 2025 - - About 30 million acne patients seek treatment in the U.S. each year - - DMT310, if approved, could be the first once-weekly topical product for the treatment of acne - SAN DIEGO, CA / ACCESSWIRE / July 17, 2024 / Derm...
SAN DIEGO, CA / ACCESSWIRE / May 17, 2024 / Dermata Therapeutics, Inc. (Nasdaq:DRMA)(Nasdaq:DRMAW) ("Dermata," or the "Company"), a late-stage biotechnology company focused on the treatment of medical and aesthetic skin diseases and conditions, today announced the entry into definitive agreement...
- DMT310 Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial enrollment remains on track - - Dermata continues discussions with potential botulinum toxin partners for DMT410 - - Received issuance of Japanese patent for DMT410 for the treatment of hyperhidrosis - SAN...